Pharmion withdraws European thalidomide application
Executive Summary
Pharmion withdraws its application for thalidomide in the treatment of multiple myeloma from the European Medicines Evaluation Agency, the company announces May 19. Pharmion said it will resubmit the application, which may allow for a broader label to include first line use. Pharmion partner Celgene has a thalidomide sNDA pending at FDA for use in multiple myeloma. Pharmion will evaluate whether Celgene's data is useful for European regulatory authorities...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.